Sree Rayalaseema Hi-Strength Hypo Q2 PAT Rises 40.4% to ₹32.70 Crore

Sree Rayalaseema Hi-Strength Hypo Limited reported consolidated Q2 FY27 profit after tax of ₹32.70 crore, up 40.4% year on year, while revenue increased 35.1% to ₹246.41 crore. The results, declared on 14 November 2026, indicate higher quarterly sales and operating profit compared with the corresponding quarter a year earlier.

What did Sree Rayalaseema Hi-Strength Hypo report for Q2 FY27?

Sree Rayalaseema Hi-Strength Hypo reported consolidated revenue of ₹246.41 crore for the quarter ended September 2026, compared with ₹182.39 crore in Q2 FY26. Consolidated profit after tax rose to ₹32.70 crore from ₹23.29 crore in the year-earlier period.

Operating profit was reported at ₹35.21 crore, against ₹26.95 crore in Q2 FY26. This represented year-on-year growth of 30.65%, while the growth in net profit was higher at 40.4%. The figures show that both revenue and reported profitability improved on an annual comparison basis.

How were the results approved and disclosed?

The board of Sree Rayalaseema Hi-Strength Hypo met on 14 November 2026 to consider and approve unaudited standalone and consolidated financial results for the second quarter and half year ended 30 September 2026. The regulatory disclosure was addressed to BSE Limited and the National Stock Exchange of India Ltd.

The filing includes the approved financial statements, limited review reports, segment-performance disclosures and cash-flow information. A limited review is the review process applied to unaudited interim financial statements and is distinct from a full-year audit.

The company’s reported Q2 comparison places the latest performance against the September 2025 quarter. In that earlier quarter, reported revenue was ₹182.39 crore and PAT was ₹23.29 crore. The latest release therefore marks a higher base for sales, operating profit and profit after tax than the prior-year quarter.

What do the approved half-year disclosures show?

The approved half-year disclosure reported standalone revenue of ₹256.60 crore and standalone PAT of ₹33.13 crore for the half year ended 30 September 2026. Consolidated revenue was reported at ₹256.59 crore, while consolidated PAT was ₹32.70 crore.

These figures were originally stated in lakhs and have been converted to crore for consistent presentation. Standalone revenue of ₹25,660.36 lakh equals ₹256.60 crore, and standalone PAT of ₹3,313.42 lakh equals ₹33.13 crore. Consolidated revenue of ₹25,658.71 lakh equals ₹256.59 crore, while consolidated PAT of ₹3,269.64 lakh equals ₹32.70 crore.

The figures in the half-year disclosure and the separately reported quarterly comparison should be read as presented in the supplied disclosures. The material does not provide a reconciliation between the reported half-year figures and the Q2 FY27 revenue comparison, so no further calculation has been made from them.

How does the latest quarter compare with earlier reported periods?

Sree Rayalaseema Hi-Strength Hypo had reported Q2 FY26 revenue of ₹189.49 crore and PAT of ₹23.29 crore in another set of financial-report data. That disclosure said total expenses were ₹157.66 crore, up 2.0% sequentially and 9.8% year on year, and reported earnings per share of ₹13.57.

For the six months ended September 2025, the company had reported revenue of ₹380.13 crore and net income of ₹46.34 crore. The comparable second-quarter revenue reported for September 2025 was ₹189.49 crore, while sales were ₹182.39 crore. Revenue and sales are separate line items in the provided historical data and should not be treated as interchangeable.

The September 2025 quarter also showed pressure on profitability in one reported comparison, with PAT down 7.9% year on year despite revenue growth. Against that background, the Q2 FY27 release is notable because the reported year-on-year increase in PAT, at 40.4%, exceeded the reported revenue increase of 35.1%.

Why do the Q2 FY27 figures matter for investors?

The Q2 FY27 figures matter because Sree Rayalaseema Hi-Strength Hypo reported simultaneous growth in revenue, operating profit and PAT. Revenue increased by ₹64.02 crore from the year-earlier quarter, while PAT increased by ₹9.41 crore. These changes provide the clearest reported measures of the quarter’s scale and earnings growth.

The company is described in the supplied information as India’s sole manufacturer of calcium hypochlorite. Its earlier results were affected by margin pressure associated with the commodity chemicals sector, including higher expenses and material costs. The current quarterly release provides reported profit and operating-profit comparisons, but it does not provide enough detail in the supplied material to identify the precise drivers of the improvement.

For shareholders, the release establishes a stronger year-on-year quarterly financial comparison. However, the supplied information does not state a post-results share-price reaction for 14 November 2026, guidance for the rest of FY27, or a specific production, pricing or demand outlook. These remain relevant areas for investors reviewing subsequent company disclosures.

Conclusion

Sree Rayalaseema Hi-Strength Hypo reported Q2 FY27 consolidated revenue of ₹246.41 crore and PAT of ₹32.70 crore, representing year-on-year growth of 35.1% and 40.4%, respectively. Operating profit also increased to ₹35.21 crore, while the board approved the unaudited standalone and consolidated results on 14 November 2026.

Investors will next watch for any detailed explanation of the growth in revenue and profitability, the company’s segment and cash-flow disclosures, and future filings that clarify performance through the remainder of FY27. The supplied results do not disclose a forward target or scheduled operational milestone.